180 related articles for article (PubMed ID: 38187473)
1. High iNOS and IL-1β immunoreactivity are features of colitis-associated colorectal cancer tumors, but fail to predict 5-year survival.
Björner K; Chen WN; Gannavarapu VR; Axling F; Gulyas M; Halim MA; Webb DL; Hellström PM
Ups J Med Sci; 2023; 28():. PubMed ID: 38187473
[TBL] [Abstract][Full Text] [Related]
2. Differential Immune Infiltration Profiles in Colitis-Associated Colorectal Cancer versus Sporadic Colorectal Cancer.
Schardey J; Lu C; Neumann J; Wirth U; Li Q; Jiang T; Zimmermann P; Andrassy J; Bazhin AV; Werner J; Kühn F
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835436
[TBL] [Abstract][Full Text] [Related]
3. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines.
Kolios G; Rooney N; Murphy CT; Robertson DA; Westwick J
Gut; 1998 Jul; 43(1):56-63. PubMed ID: 9771406
[TBL] [Abstract][Full Text] [Related]
4. Expression of inducible nitric oxide synthase (iNOS) mRNA in inflamed esophageal and colonic mucosa in a pediatric population.
Gupta SK; Fitzgerald JF; Chong SK; Croffie JM; Garcia JG
Am J Gastroenterol; 1998 May; 93(5):795-8. PubMed ID: 9625130
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.
Isidro RA; Cruz ML; Isidro AA; Baez A; Arroyo A; González-Marqués WA; González-Keelan C; Torres EA; Appleyard CB
World J Gastroenterol; 2015 Feb; 21(6):1749-58. PubMed ID: 25684939
[TBL] [Abstract][Full Text] [Related]
6. Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis.
Kankuri E; Hämäläinen M; Hukkanen M; Salmenperä P; Kivilaakso E; Vapaatalo H; Moilanen E
Scand J Gastroenterol; 2003 Feb; 38(2):186-92. PubMed ID: 12678336
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA 301A Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting BTG1.
He C; Yu T; Shi Y; Ma C; Yang W; Fang L; Sun M; Wu W; Xiao F; Guo F; Chen M; Yang H; Qian J; Cong Y; Liu Z
Gastroenterology; 2017 May; 152(6):1434-1448.e15. PubMed ID: 28193514
[TBL] [Abstract][Full Text] [Related]
8. The physiological expression of inducible nitric oxide synthase (iNOS) in the human colon.
Roberts PJ; Riley GP; Morgan K; Miller R; Hunter JO; Middleton SJ
J Clin Pathol; 2001 Apr; 54(4):293-7. PubMed ID: 11304846
[TBL] [Abstract][Full Text] [Related]
9. Expression of nitric oxide synthase in inflammatory bowel disease is not affected by corticosteroid treatment.
Leonard N; Bishop AE; Polak JM; Talbot IC
J Clin Pathol; 1998 Oct; 51(10):750-3. PubMed ID: 10023337
[TBL] [Abstract][Full Text] [Related]
10. Induction of inducible nitric oxide synthase: a protective mechanism in colitis-induced adenocarcinoma.
Zhang R; Ma A; Urbanski SJ; McCafferty DM
Carcinogenesis; 2007 May; 28(5):1122-30. PubMed ID: 17116728
[TBL] [Abstract][Full Text] [Related]
11. Association of elevated glial expression of interleukin-1beta with improved survival in patients with glioblastomas multiforme.
Cuny E; Loiseau H; Penchet G; Ellie E; Arsaut J; Vital A; Vincendeau P; Demotes-Mainard J
J Neurosurg; 2002 Feb; 96(2):294-301. PubMed ID: 11838804
[TBL] [Abstract][Full Text] [Related]
12. Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease.
Palatka K; Serfozo Z; Veréb Z; Hargitay Z; Lontay B; Erdodi F; Bánfalvi G; Nemes Z; Udvardy M; Altorjay I
Scand J Gastroenterol; 2005 Jun; 40(6):670-80. PubMed ID: 16036527
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathogenesis of Colitis-associated Colorectal Cancer: Immunity, Genetics, and Intestinal Microecology.
Yin Y; Wan J; Yu J; Wu K
Inflamm Bowel Dis; 2023 Oct; 29(10):1648-1657. PubMed ID: 37202830
[TBL] [Abstract][Full Text] [Related]
14. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease.
Singer II; Kawka DW; Scott S; Weidner JR; Mumford RA; Riehl TE; Stenson WF
Gastroenterology; 1996 Oct; 111(4):871-85. PubMed ID: 8831582
[TBL] [Abstract][Full Text] [Related]
15. Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma.
Liu X; Goldblum JR; Zhao Z; Landau M; Heald B; Pai R; Lin J
Am J Surg Pathol; 2012 Aug; 36(8):1228-33. PubMed ID: 22790862
[TBL] [Abstract][Full Text] [Related]
16. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies.
Fantini MC; Guadagni I
Dig Liver Dis; 2021 May; 53(5):558-565. PubMed ID: 33541800
[TBL] [Abstract][Full Text] [Related]
17. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
18. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.
Rafa H; Saoula H; Belkhelfa M; Medjeber O; Soufli I; Toumi R; de Launoit Y; Moralès O; Nakmouche M; Delhem N; Touil-Boukoffa C
J Interferon Cytokine Res; 2013 Jul; 33(7):355-68. PubMed ID: 23472658
[TBL] [Abstract][Full Text] [Related]
19.
Silveira DSC; Veronez LC; Lopes-Júnior LC; Anatriello E; Brunaldi MO; Pereira-da-Silva G
World J Gastroenterol; 2020 Nov; 26(43):6782-6794. PubMed ID: 33268961
[TBL] [Abstract][Full Text] [Related]
20. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease.
Kimura H; Miura S; Shigematsu T; Ohkubo N; Tsuzuki Y; Kurose I; Higuchi H; Akiba Y; Hokari R; Hirokawa M; Serizawa H; Ishii H
Dig Dis Sci; 1997 May; 42(5):1047-54. PubMed ID: 9149061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
